image credit: Unsplash

Immunomedics wins long-sought FDA approval for breast cancer drug

April 22, 2020

Trodelvy is Immunomedics’ first approved drug in its nearly four-decade-long corporate history. The biotech’s transition from a research organization to a commercial-stage biotech, though, comes in the middle of a pandemic and at a time when drugmakers have largely grounded traditional in-person sales efforts.

Cancer drugs, though, appear to be less affected by disruption from the spread of the new coronavirus, chiefly due to the critical need for treatment.

Read More on Biopharma Dive